Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies

[Background] Patients with relapsed/refractory multiple myeloma (RRMM) who develop extramedullary disease (EMD) generally have a poor prognosis, highlighting the urgent need for new therapies. We report effectiveness outcomes and safety in patients with and without EMD from the pooled analysis of Lo...

Descripción completa

Detalles Bibliográficos
Autores: Moreau, Philippe, Mateos, Maria Victoria, Goldschmidt, Hartmut, González García, María-Esther, Besemer, Britta, González Pérez, Marta Sonia, Mohty, Mohamad, Lindsey-Hill, Joanne, Kirkpatrick, Suriya, Delforge, Michel, Angelucci, Emanuele, Raimondo, Francesco Di, Vij, Ravi, Doyle, Margaret, Gray, Kathleen, Albrecht, Claire, Strulev, Vadim, Haddad, Imène, Koskinen, Silva, Acciarri, Lorenzo, Buyze, Jozefien, Weisel, Katja
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:dnet:digitalcsic_::943641df23d30fe56c0f7d2573901af1
Acceso en línea:http://hdl.handle.net/10261/426142
https://api.elsevier.com/content/abstract/scopus_id/105003942547
Access Level:acceso abierto
Palabra clave:Extramedullary plasmacytoma
Real-life outcomes
Prospective
Standard-of-care
Treatment
id ES_0fd2e596f22ca9d053408bdcca1ebdf2
oai_identifier_str oai:dnet:digitalcsic_::943641df23d30fe56c0f7d2573901af1
network_acronym_str ES
network_name_str España
repository_id_str
spelling Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent StudiesMoreau, PhilippeMateos, Maria VictoriaGoldschmidt, HartmutGonzález García, María-EstherBesemer, BrittaGonzález Pérez, Marta SoniaMohty, MohamadLindsey-Hill, JoanneKirkpatrick, SuriyaDelforge, MichelAngelucci, EmanueleRaimondo, Francesco DiVij, RaviDoyle, MargaretGray, KathleenAlbrecht, ClaireStrulev, VadimHaddad, ImèneKoskinen, SilvaAcciarri, LorenzoBuyze, JozefienWeisel, KatjaExtramedullary plasmacytomaReal-life outcomesProspectiveStandard-of-careTreatment[Background] Patients with relapsed/refractory multiple myeloma (RRMM) who develop extramedullary disease (EMD) generally have a poor prognosis, highlighting the urgent need for new therapies. We report effectiveness outcomes and safety in patients with and without EMD from the pooled analysis of LocoMMotion and MoMMent.[Methods] LocoMMotion and MoMMent-1 are prospective, noninterventional, consecutive studies assessing the evolving standard of care from 20192022 in patients with triple-class exposed RRMM.[Results] Of 302 patients, 29 had EMD per investigator discretion and only 15 patients were assessed as having true extramedullary plasmacytoma (EMP; defined as patients with ≥1 EMP lesion) by the response review committee. The 29 EMD patients received 21 unique regimens (most commonly chemotherapy-based regimens). Of the 29 patients with EMD, overall response rate (ORR) was 24.1%, median progression-free survival (PFS) was 2.66 months, median overall survival (OS) was 7.16 months, and median time to next treatment (TTNT) was 3.09 months. All responses were lower (ORR) and shorter (median PFS, OS, and TTNT) in patients with EMD vs patients without EMD. Nineteen (65.5%) patients with EMD received ≥1 subsequent lines of therapy. Of those, two (10.5%) patients received bispecific antibodies and achieved a partial response or better; three (15.8%) patients received antibody-drug conjugates (responses were unknown or not determined at data cut-off), and no patients received chimeric antigen receptorT cell therapy.[Conclusions] These results demonstrate the urgent need for more effective novel therapies for patients with EMD and highlight the need to use clear definitions of EMD and EMD response criteria for clinical trials.Medical writing support was provided by Ashley Thoma, PharmD, of Eloquent Scientific Solutions, and funded by Johnson & Johnson. LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) was funded by Johnson & Johnson and Legend Biotech USA Inc. MoMMent (ClinicalTrials.gov identifier: NCT05160584) was funded by Johnson & Johnson.Peer reviewedElsevierJohnson & Johnson ServicesConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202620262025info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/426142https://api.elsevier.com/content/abstract/scopus_id/105003942547reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://doi.org/10.1016/j.clml.2025.03.014Síinfo:eu-repo/semantics/openAccessoai:dnet:digitalcsic_::943641df23d30fe56c0f7d2573901af12026-05-22T06:33:51Z
dc.title.none.fl_str_mv Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies
title Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies
spellingShingle Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies
Moreau, Philippe
Extramedullary plasmacytoma
Real-life outcomes
Prospective
Standard-of-care
Treatment
title_short Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies
title_full Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies
title_fullStr Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies
title_full_unstemmed Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies
title_sort Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies
dc.creator.none.fl_str_mv Moreau, Philippe
Mateos, Maria Victoria
Goldschmidt, Hartmut
González García, María-Esther
Besemer, Britta
González Pérez, Marta Sonia
Mohty, Mohamad
Lindsey-Hill, Joanne
Kirkpatrick, Suriya
Delforge, Michel
Angelucci, Emanuele
Raimondo, Francesco Di
Vij, Ravi
Doyle, Margaret
Gray, Kathleen
Albrecht, Claire
Strulev, Vadim
Haddad, Imène
Koskinen, Silva
Acciarri, Lorenzo
Buyze, Jozefien
Weisel, Katja
author Moreau, Philippe
author_facet Moreau, Philippe
Mateos, Maria Victoria
Goldschmidt, Hartmut
González García, María-Esther
Besemer, Britta
González Pérez, Marta Sonia
Mohty, Mohamad
Lindsey-Hill, Joanne
Kirkpatrick, Suriya
Delforge, Michel
Angelucci, Emanuele
Raimondo, Francesco Di
Vij, Ravi
Doyle, Margaret
Gray, Kathleen
Albrecht, Claire
Strulev, Vadim
Haddad, Imène
Koskinen, Silva
Acciarri, Lorenzo
Buyze, Jozefien
Weisel, Katja
author_role author
author2 Mateos, Maria Victoria
Goldschmidt, Hartmut
González García, María-Esther
Besemer, Britta
González Pérez, Marta Sonia
Mohty, Mohamad
Lindsey-Hill, Joanne
Kirkpatrick, Suriya
Delforge, Michel
Angelucci, Emanuele
Raimondo, Francesco Di
Vij, Ravi
Doyle, Margaret
Gray, Kathleen
Albrecht, Claire
Strulev, Vadim
Haddad, Imène
Koskinen, Silva
Acciarri, Lorenzo
Buyze, Jozefien
Weisel, Katja
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Johnson & Johnson Services
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Extramedullary plasmacytoma
Real-life outcomes
Prospective
Standard-of-care
Treatment
topic Extramedullary plasmacytoma
Real-life outcomes
Prospective
Standard-of-care
Treatment
description [Background] Patients with relapsed/refractory multiple myeloma (RRMM) who develop extramedullary disease (EMD) generally have a poor prognosis, highlighting the urgent need for new therapies. We report effectiveness outcomes and safety in patients with and without EMD from the pooled analysis of LocoMMotion and MoMMent.
publishDate 2025
dc.date.none.fl_str_mv 2025
2026
2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/426142
https://api.elsevier.com/content/abstract/scopus_id/105003942547
url http://hdl.handle.net/10261/426142
https://api.elsevier.com/content/abstract/scopus_id/105003942547
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.1016/j.clml.2025.03.014
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403475963543552
score 15,812429

Similares en LA Referencia